The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa

M. A. Walton, C. Villarreal, David Herndon, J. P. Heggers

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The emergence of multi-resistant Gram-negative bacteria has created a most alarming clinical situation. The armamentarium of antibiotics used against this group of organisms is rapidly being depleted. Our routine therapeutic approach to control and prevent these Gram-negative bacteria from gaining a foothold was the empirical use of an aminoglycoside combined with piperacillin. However, aminoglycoside resistance is now routine rather than unusual. We evaluated the role of the monobactam aztreonam in burn wound infections and compared it to the aminoglycosides amikacin and gentamicin as well as piperacillin for the Enterobacteriacae and Pseudomonas aeruginosa. A total of 1274 Gram-negative isolates including P. aeruginosa were evaluated for susceptibility to the above-mentioned antibiotics from January 1995 to August 1995 (Table I). Among the Enterobacteriacae, aztreonam was more effective than amikacin and piperacillin (58.4 per cent vs. 45.8 per cent, respectively). However it still fluctuated among the Enterobacteriacae as did the aminoglycosides. One major significant finding was that while susceptibility to aztreonam was variable for the Enterobacteriacae, P. aeruginosa remained 90 per cent susceptible to aztreonam and 90 per cent susceptible to piperacillin, whereas it was 79 per cent resistant to the aminoglycosides. Consequently, when choosing an antimicrobial in a suspected P. aeruginosa burn wound infection, aztreonam and piperacillin should be considered as the first line of defense.

Original languageEnglish (US)
Pages (from-to)225-227
Number of pages3
JournalBurns
Volume23
Issue number3
DOIs
StatePublished - May 1997

Fingerprint

Aztreonam
Piperacillin
Aminoglycosides
Pseudomonas aeruginosa
Amikacin
Wound Infection
Gram-Negative Bacteria
Monobactams
Anti-Bacterial Agents
Therapeutics
Gentamicins

Keywords

  • Aztreonam
  • Multi-resistant
  • Pseudomonas aeruginosa
  • Therapy

ASJC Scopus subject areas

  • Emergency Medicine
  • Surgery

Cite this

The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa. / Walton, M. A.; Villarreal, C.; Herndon, David; Heggers, J. P.

In: Burns, Vol. 23, No. 3, 05.1997, p. 225-227.

Research output: Contribution to journalArticle

Walton, MA, Villarreal, C, Herndon, D & Heggers, JP 1997, 'The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa', Burns, vol. 23, no. 3, pp. 225-227. https://doi.org/10.1016/S0305-4179(96)00126-X
Walton, M. A. ; Villarreal, C. ; Herndon, David ; Heggers, J. P. / The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa. In: Burns. 1997 ; Vol. 23, No. 3. pp. 225-227.
@article{656f3b2c0de3450081449a80f1ab5860,
title = "The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa",
abstract = "The emergence of multi-resistant Gram-negative bacteria has created a most alarming clinical situation. The armamentarium of antibiotics used against this group of organisms is rapidly being depleted. Our routine therapeutic approach to control and prevent these Gram-negative bacteria from gaining a foothold was the empirical use of an aminoglycoside combined with piperacillin. However, aminoglycoside resistance is now routine rather than unusual. We evaluated the role of the monobactam aztreonam in burn wound infections and compared it to the aminoglycosides amikacin and gentamicin as well as piperacillin for the Enterobacteriacae and Pseudomonas aeruginosa. A total of 1274 Gram-negative isolates including P. aeruginosa were evaluated for susceptibility to the above-mentioned antibiotics from January 1995 to August 1995 (Table I). Among the Enterobacteriacae, aztreonam was more effective than amikacin and piperacillin (58.4 per cent vs. 45.8 per cent, respectively). However it still fluctuated among the Enterobacteriacae as did the aminoglycosides. One major significant finding was that while susceptibility to aztreonam was variable for the Enterobacteriacae, P. aeruginosa remained 90 per cent susceptible to aztreonam and 90 per cent susceptible to piperacillin, whereas it was 79 per cent resistant to the aminoglycosides. Consequently, when choosing an antimicrobial in a suspected P. aeruginosa burn wound infection, aztreonam and piperacillin should be considered as the first line of defense.",
keywords = "Aztreonam, Multi-resistant, Pseudomonas aeruginosa, Therapy",
author = "Walton, {M. A.} and C. Villarreal and David Herndon and Heggers, {J. P.}",
year = "1997",
month = "5",
doi = "10.1016/S0305-4179(96)00126-X",
language = "English (US)",
volume = "23",
pages = "225--227",
journal = "Burns",
issn = "0305-4179",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa

AU - Walton, M. A.

AU - Villarreal, C.

AU - Herndon, David

AU - Heggers, J. P.

PY - 1997/5

Y1 - 1997/5

N2 - The emergence of multi-resistant Gram-negative bacteria has created a most alarming clinical situation. The armamentarium of antibiotics used against this group of organisms is rapidly being depleted. Our routine therapeutic approach to control and prevent these Gram-negative bacteria from gaining a foothold was the empirical use of an aminoglycoside combined with piperacillin. However, aminoglycoside resistance is now routine rather than unusual. We evaluated the role of the monobactam aztreonam in burn wound infections and compared it to the aminoglycosides amikacin and gentamicin as well as piperacillin for the Enterobacteriacae and Pseudomonas aeruginosa. A total of 1274 Gram-negative isolates including P. aeruginosa were evaluated for susceptibility to the above-mentioned antibiotics from January 1995 to August 1995 (Table I). Among the Enterobacteriacae, aztreonam was more effective than amikacin and piperacillin (58.4 per cent vs. 45.8 per cent, respectively). However it still fluctuated among the Enterobacteriacae as did the aminoglycosides. One major significant finding was that while susceptibility to aztreonam was variable for the Enterobacteriacae, P. aeruginosa remained 90 per cent susceptible to aztreonam and 90 per cent susceptible to piperacillin, whereas it was 79 per cent resistant to the aminoglycosides. Consequently, when choosing an antimicrobial in a suspected P. aeruginosa burn wound infection, aztreonam and piperacillin should be considered as the first line of defense.

AB - The emergence of multi-resistant Gram-negative bacteria has created a most alarming clinical situation. The armamentarium of antibiotics used against this group of organisms is rapidly being depleted. Our routine therapeutic approach to control and prevent these Gram-negative bacteria from gaining a foothold was the empirical use of an aminoglycoside combined with piperacillin. However, aminoglycoside resistance is now routine rather than unusual. We evaluated the role of the monobactam aztreonam in burn wound infections and compared it to the aminoglycosides amikacin and gentamicin as well as piperacillin for the Enterobacteriacae and Pseudomonas aeruginosa. A total of 1274 Gram-negative isolates including P. aeruginosa were evaluated for susceptibility to the above-mentioned antibiotics from January 1995 to August 1995 (Table I). Among the Enterobacteriacae, aztreonam was more effective than amikacin and piperacillin (58.4 per cent vs. 45.8 per cent, respectively). However it still fluctuated among the Enterobacteriacae as did the aminoglycosides. One major significant finding was that while susceptibility to aztreonam was variable for the Enterobacteriacae, P. aeruginosa remained 90 per cent susceptible to aztreonam and 90 per cent susceptible to piperacillin, whereas it was 79 per cent resistant to the aminoglycosides. Consequently, when choosing an antimicrobial in a suspected P. aeruginosa burn wound infection, aztreonam and piperacillin should be considered as the first line of defense.

KW - Aztreonam

KW - Multi-resistant

KW - Pseudomonas aeruginosa

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0030814355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030814355&partnerID=8YFLogxK

U2 - 10.1016/S0305-4179(96)00126-X

DO - 10.1016/S0305-4179(96)00126-X

M3 - Article

C2 - 9232282

AN - SCOPUS:0030814355

VL - 23

SP - 225

EP - 227

JO - Burns

JF - Burns

SN - 0305-4179

IS - 3

ER -